The United Kingdom and the United States have agreed to a major bilateral deal that will maintain zero levies on UK medicine products being sold in the American market.
Key Provisions of the Accord
As part of the deal, the UK has committed to raise spending on pharmaceuticals through the National Health Service (NHS). This commitment ensures that import taxes on these vital products will remain at zero for a duration of three years.
This agreement follows recent threats to dramatically increase import taxes on patented pharmaceutical products, with figures discussed up to one hundred percent.
"This deal with the United Kingdom reinforces the worldwide climate for innovative medicines and introduces much-needed fairness to transatlantic medicine commerce," a statement declared.
Commercial Impact
Pharmaceuticals constitute one of the Britain's largest exports to the US, which is easily the largest market for large companies like GSK and AstraZeneca.
Statistics indicate that in the 12 months leading up to September, the UK sold pharmaceutical products totaling £11.1bn to the US. This value made up nearly one-fifth of British export trade in that period.
"This agreement protects jobs, stimulates capital expenditure and paves the way for the UK to emerge as a international leader for biotech and pharma," the Business and Trade Secretary commented.
Key UK Commitments
The deal includes several key pledges from the British government:
- Revised Affordability Limit: The UK will lift the price threshold at which it considers new medicines to be unaffordable by twenty-five percent.
- Boosted Medicine Funding: There is a target to double total NHS spending on treatments from 0.3 percent of GDP to 0.6 percent over the coming ten years.
- Rebate Cap: The sum manufacturers must pay back to the NHS to prevent overspending will be capped at 15%. Last year, repayments exceeded 20%.
Industry Background
The pact takes place against a ongoing dispute between the sector and the ministers over medicine costs and approval rates.
This friction were exacerbated by claims that American customers were paying significantly more for the identical medicines than patients in the other developed nations.
Recently, several significant pharmaceutical investments in the UK have been delayed or abandoned, while multi-billion-dollar expansions have been pledged toward US facilities.
A senior figure publicly accepted that the NHS must increase expenditure on drugs, noting that its budget allocation on drugs had shrunk as a percentage of its resources over the past decade.
